Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNurExone Biologic Inc.

NurExone Biologic Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.475 CAD -0.03 ( 5.00%)
Last update at 2026-11-04T16:19:00Z
VOLUME
15803
Market Cap
57.99M

Momentum Score

…

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.47
Low
0.50
High
52 Week Price Range
0.57
Low
1.14
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on NurExone Biologic Inc. is limited; the company is listed on the TSX Venture Exchange and appears to focus on biologics, though specific pipeline or commercial activities are not readily available. Long-term growth may depend on successful research and development, regulatory progress, strategic partnerships and access to capital, which could support valuation if clinical or commercial milestones are achieved.
Key investment risks include early-stage status with limited disclosure, heavy dependence on successful clinical and regulatory outcomes and significant financing and dilution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.50
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-1.44M
Debt / Equity
-
ROE
-282.54%
Net Debt
-
ROCE
-204.36%
Diluted EPS TTM
-0.11

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.38M -5.04M -3.64M -8.17M -1.65M
Net income -6.38M -5.04M -3.64M -8.17M -1.65M
Selling general administrative 3.65M 3.11M 2.10M 4.14M 1.14M
Reconciled depreciation 0.18M 0.09M 0.03M 0.01M 0.00M
Operating income -6.32M -5.01M -3.66M -5.54M -1.71M
Interest expense 0.03M 0.02M 0.00M 0.03M 0.01M
Interest income 0.01M - - - -
Net interest income -0.02M 0.03M 0.04M -0.02M -0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 6.32M 5.01M 3.66M 5.54M 1.71M
Total other income expense net -0.04M -0.07M -0.02M -2.61M 0.08M
Net income from continuing ops -6.38M -5.04M -3.64M -8.17M -1.65M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 4.08M 2.44M 2.17M 2.79M 2.84M
Total liab 1.32M 0.68M 1.98M 0.70M 1.66M
Total stockholder equity 2.76M 1.76M 0.19M 2.10M 1.18M
Other current liab 0.23M - 1.20M - 0.24M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -25.48M -19.10M -14.06M -10.42M -2.25M
Cash 2.14M 0.70M 0.54M 2.46M 2.21M
Total current liabilities 0.99M 0.40M 1.91M 0.60M 1.63M
Short long term debt - - - - 1.04M
Total current assets 2.60M 1.63M 1.98M 2.69M 2.84M
Non currrent assets other 0.62M - - 0.00M -
Non current assets total 1.48M 0.81M 0.19M 0.10M 0.00M
Capital lease obligations 0.11M 0.03M 0.02M 0.04M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.66M -0.10M -0.09M -0.02M
Net borrowings -0.02M -0.03M - - -
Total cash from financing activities 5.83M 5.88M 1.13M 4.29M 3.46M
Net income -6.38M -5.04M -3.64M -8.17M -1.65M
Change in cash 1.44M 0.16M -1.92M 0.25M 2.21M
Begin period cash flow 0.70M 0.54M 2.46M 2.21M 0.00M
End period cash flow 2.14M 0.70M 0.54M 2.46M 2.21M
Total cash from operating activities -4.51M -4.89M -2.94M -3.85M -1.23M
Issuance of capital stock 2.90M 2.71M 0.74M 2.33M 2.23M
Depreciation 0.18M 0.09M 0.03M 0.01M 0.00M
Change to inventory -0.02M - - - -
Capital expenditures 0.06M 0.65M 0.12M 0.05M 0.00M
Change in working capital 0.37M -0.92M 0.00M 0.24M 0.29M
Stock based compensation 1.29M 0.94M 0.64M 0.23M 0.17M
Other non cash items 0.03M 0.06M 0.02M 3.69M 0.01M
Free cash flow -4.57M -5.54M -3.06M -3.90M -1.23M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NRX
NurExone Biologic Inc.		 -0.03
5.00%		 0.47 - 6.90 - 15.26 -7.24
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 -
MIR
MedMira Inc		 -0.01
9.09%		 0.05 - - 223.37 - -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 -58.16
ARCH
Arch Biopartners Inc		 -0.03
3.41%		 0.85 - - 197.68 6211.54 6970.51

Profile*

NurExone Biologic Inc.

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.

1 Adelaide Street East, Toronto, ON, Canada, M5C 2V9

https://nurexone.com

Name Title Year Born
Mr. Yoram Drucker VP of Strategic Devel. & Chairman 1965
Dr. Lior Shaltiel CEO & Director NA
Mr. Eran Ovadya M.B.A. Chief Financial Officer NA
Mr. Eyal Flom L.L.M., M.B.A. Legal Counsel & Director 1966
Ms. Inbar Paz-Benayoun Head of Corp. Communications NA
Gabriel Eldor VP of Strategic Operations & Director NA
Meni Sofiof Financial Controller NA
Mr. Yoram Drucker Co-Founder, VP of Strategic Development & Chairman 1965
Dr. Lior Shaltiel Ph.D. CEO & Director NA
Mr. Eran Ovadya M.B.A. CFO, Financial Director & Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 29.99
+13.13%
AP-UN
CAD 4.19
+12.94%
ARTG
CAD 39.66
+12.93%
BZ
CAD 4.14
+10.99%
FFH
CAD 2759.48
+10.87%
DRUG
CAD 27.12
-26.86%
HUT
CAD 69.10
-22.27%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.85
-14.43%
MOON
CAD 4.09
-12.79%

Equity Sectors*

  • Basic Materials

    +3.69%

  • Communication Services

    +2.61%

  • Consumer Cyclical

    +2.96%

  • Consumer Defensive

    +1.11%

  • Energy

    -5.01%

  • Financial Services

    +2.20%

  • Healthcare

    -0.56%

  • Industrials

    -0.73%

  • Real Estate

    +1.90%

  • Technology

    +0.05%

  • Utilities

    +1.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…